Investor Presentaiton

Performance: 2022 adj. operating profit to adj. profit attributable to shareholders' 2021 2022 £m £m Operating profit 6,493 8,151 Net finance expense (752) (791) Key commentary +26% at AER, +14% at CER (ex- pandemic² +17% at CER) Sterling Notes repurchase in November Share of associates 33 (2) Ταχ (918) (1,138) Tax rate 15.9% 15.5% Non-controlling interests (441) (595) Reflects timing of settlements with various tax authorities Increased allocation of ViiV profits Profit attributable to shareholders 4,415 5,625 +27% at AER, +15% at CER 1. GSK continuing operations only and Adjusted results 2. Excluding COVID-19 solutions GSK 23

View entire presentation